Answers are grounded in this paper and cite their sources.
Early observations of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) transmission via lung transplantation have led to frequent discard of lungs from donors with positive SARS-CoV-2 tests. We compared survival between lung transplant recipients (LUTRs) with SARS-CoV-2 (+) ( n = 11) and SARS-CoV-2 (-) donors ( n = 192) transplanted from January 30, 2022 to March 31, 2024. Three of the 11 SARS-CoV-2 (+) donors had positive lower respiratory tract (LRT) tests. Two of their 3 recipients developed post-transplant SARS-CoV-2 infections, including one LUTR who died 11 days post-transplant. LUTRs with SARS-CoV-2 (+) donors had higher 30-day mortality (2/11 [18.2%] vs 7/192 [3.6%], p = 0.02), but there was no significant difference in 1-year mortality (2/11 [18.2%] vs 27/192 [14.1%], p = 0.56). Only 3 (27%) LUTRs with SARS-CoV-2 (+) donors developed acute cellular rejection in the first post-transplant year, and none were diagnosed with chronic lung allograft dysfunction. These findings support consideration of SARS-CoV-2 (+) lung donors, especially when LRT testing is negative.
No takes yet. Share an insight, caveat, or question.
Kothadia et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: